Dana P Ascherman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3059463/publications.pdf

Version: 2024-02-01

46 papers	2,835 citations	218381 26 h-index	233125 45 g-index
48 all docs	48 docs citations	48 times ranked	2473 citing authors

#	Article	IF	Citations
1	Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placeboâ€phase trial. Arthritis and Rheumatism, 2013, 65, 314-324.	6.7	514
2	Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Annals of the Rheumatic Diseases, 2014, 73, 227-232.	0.5	231
3	Predictors of Clinical Improvement in Rituximabâ€Treated Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis. Arthritis and Rheumatology, 2014, 66, 740-749.	2.9	210
4	Antiâ€“Joâ€1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis and Rheumatism, 2007, 56, 3125-3131.	6.7	186
5	Detection of Rheumatoid Arthritisâ€“Interstitial Lung Disease Is Enhanced by Serum Biomarkers. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1403-1412.	2.5	156
6	Characterization and peripheral blood biomarker assessment of antiâ€“Joâ€1 antibodyâ€“positive interstitial lung disease. Arthritis and Rheumatism, 2009, 60, 2183-2192.	6.7	128
7	Identification of Citrullinated Hsp90 Isoforms as Novel Autoantigens in Rheumatoid Arthritisâ€“Associated Interstitial Lung Disease. Arthritis and Rheumatism, 2013, 65, 869-879.	6.7	113
8	Biomarkers of Rheumatoid Arthritisâ€“Associated Interstitial Lung Disease. Arthritis and Rheumatology, 2015, 67, 28-38.	2.9	92
9	Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurology, The, 2019, 18, 834-844.	4.9	91
10	Species-specific immune responses generated by histidyl-tRNA synthetase immunization are associated with muscle and lung inflammation. Journal of Autoimmunity, 2007, 29, 174-186.	3.0	83
11	Functional Impact of a Spectrum of Interstitial Lung Abnormalities in Rheumatoid Arthritis. Chest, 2014, 146, 41-50.	0.4	78
12	Pulmonary Manifestations of Polymyositis/Dermatomyositis. Seminars in Respiratory and Critical Care Medicine, 2014, 35, 239-248.	0.8	70
13	A Roadmap to Promote Clinical and Translational Research in Rheumatoid Arthritis-Associated Interstitial Lung Disease. Chest, 2014, 145, 454-463.	0.4	67
14	Interstitial Lung Disease in Rheumatoid Arthritis. Current Rheumatology Reports, 2010, 12, 363-369.	2.1	54
15	Asymptomatic Preclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease. Clinical and Developmental Immunology, 2013, 2013, 1-5.	3.3	52
16	Malondialdehydeâ€“Acetaldehyde Adducts and Antibody Responses in Rheumatoid Arthritisâ€“Associated Interstitial Lung Disease. Arthritis and Rheumatology, 2019, 71, 1483-1493.	2.9	50
17	Rheumatoid Arthritis-Associated Interstitial Lung Disease: Current Concepts. Current Rheumatology Reports, 2017, 19, 79.	2.1	45
18	Role of innate immunity in a murine model of histidylâ€“transfer RNA synthetase (Joâ€1)â€“mediated myositis. Arthritis and Rheumatism, 2011, 63, 479-487.	6.7	44

#	Article	IF	Citations
19	Biologic predictors of clinical improvement in rituximab-treated refractory myositis. BMC Musculoskeletal Disorders, 2015, 16, 257.	0.8	42
20	Rheumatoid Arthritis-Associated Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis: Shared Mechanistic and Phenotypic Traits Suggest Overlapping Disease Mechanisms. Revista De Investigacion Clinica, 2015, 67, 280-6.	0.2	42
21	Structural and Thermodynamic Approach to Peptide Immunogenicity. PLoS Computational Biology, 2008, 4, e1000231.	1.5	39
22	Temporal relationship between cancer and myositis identifies two distinctive subgroups of cancers: impact on cancer risk and survival in patients with myositis. Rheumatology, 2016, 55, 1631-1641.	0.9	34
23	Comparative Profiling of Serum Protein Biomarkers in Rheumatoid Arthritisâ€“Associated Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis. Arthritis and Rheumatology, 2020, 72, 409-419.	2.9	34
24	Extensive Citrullination Promotes Immunogenicity of HSP90 through Protein Unfolding and Exposure of Cryptic Epitopes. Journal of Immunology, 2016, 197, 1926-1936.	0.4	32
25	The role of jo-1 in the immunopathogenesis of polymyositis: Current hypotheses. Current Rheumatology Reports, 2003, 5, 425-430.	2.1	30
26	Anti-citrullinated heat shock protein 90 antibodies identified in bronchoalveolar lavage fluid are a marker of lung-specific immune responses. Clinical Immunology, 2014, 155, 60-70.	1.4	30
27	Risk Factors and Cancer Screening in Myositis. Rheumatic Disease Clinics of North America, 2020, 46, 565-576.	0.8	28
28	Critical Requirement for Professional APCs in Eliciting T Cell Responses to Novel Fragments of Histidyl-tRNA Synthetase (Jo-1) in Jo-1 Antibody-Positive Polymyositis. Journal of Immunology, 2002, 169, 7127-7134.	0.4	27
29	Role of Jo-1 in the Immunopathogenesis of the Anti-synthetase Syndrome. Current Rheumatology Reports, 2015, 17, 56.	2.1	25
30	Functional Redundancy of MyD88-Dependent Signaling Pathways in a Murine Model of Histidyl-Transfer RNA Synthetaseâ€“Induced Myositis. Journal of Immunology, 2013, 191, 1865-1872.	0.4	21
31	Reversal of New-Onset Type 1 Diabetes With an Agonistic TLR4/MD-2 Monoclonal Antibody. Diabetes, 2015, 64, 3614-3626.	0.3	21
32	Required Role of Apoptotic Myogenic Precursors and Tollâ€like Receptor Stimulation for the Establishment of Autoimmune Myositis in Experimental Murine Models. Arthritis and Rheumatology, 2015, 67, 809-822.	2.9	20
33	Immunoproteomics technologies in the discovery of autoantigens in autoimmune diseases. Biomolecular Concepts, 2016, 7, 133-143.	1.0	20
34	Pulmonary Complications of Inflammatory Myopathy. Rheumatic Disease Clinics of North America, 2015, 41, 249-262.	0.8	19
35	Association of Agricultural, Occupational, and Military Inhalants With Autoantibodies and Disease Features in US Veterans With Rheumatoid Arthritis. Arthritis and Rheumatology, 2021, 73, 392-400.	2.9	17
36	Animal Models of Inflammatory Myopathy. Current Rheumatology Reports, 2012, 14, 257-263.	2.1	13

#	Article	IF	Citations
37	Autoreactive T cells to citrullinated HSP90 are associated with interstitial lung disease in rheumatoid arthritis. International Journal of Rheumatic Diseases, 2018, 21, 1398-1405.	0.9	13
38	Henoch-SchÃ¶nlein Purpura with Adalimumab Therapy for Ulcerative Colitis: A Case Report and Review of the Literature. Case Reports in Rheumatology, 2016, 2016, 1-4.	0.2	12
39	The impact of airborne endotoxin exposure on rheumatoid arthritis-related joint damage, autoantigen expression, autoimmunity, and lung disease. International Immunopharmacology, 2021, 100, 108069.	1.7	12
40	Immuno-proteomics: Development of a novel reagent for separating antibodies from their target proteins. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2015, 1854, 592-600.	1.1	9
41	Interferon-regulated chemokine score associated with improvement in disease activity in refractory myositis patients treated with rituximab. Clinical and Experimental Rheumatology, 2015, 33, 655-63.	0.4	9
42	Pulmonary complications of inflammatory myopathy. Current Rheumatology Reports, 2002, 4, 409-414.	2.1	8
43	Predictors of long-term prognosis in rheumatoid arthritis-related interstitial lung disease. Scientific Reports, 2022, 12, .	1.6	8
44	Increased susceptibility to organic dust exposure-induced inflammatory lung disease with enhanced rheumatoid arthritis-associated autoantigen expression in HLA-DR4 transgenic mice. Respiratory Research, 2022, 23, .	1.4	4
45	Severe mononeuritis multiplex after rituximab in IgMâ€Î¤ monoclonal gammopathy. Muscle and Nerve, 2018, 57, E115-E118.	1.0	2
46	Citrullinated Autoantigen Targets as Markers of Extra-Articular Disease in Rheumatoid Arthritis. , 2017, , 191-203.		0